Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Emerging drugs for hemophilia A: insights into phase II and III clinical trials67
Emerging therapeutics in Huntington’s disease24
A review of phase II and III drugs for the treatment and management of endometriosis21
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?17
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder17
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia15
New drugs targeting calcitonin gene-related peptide for the management of migraines14
Emerging drugs for the treatment of postsurgical pain13
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials13
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review12
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials11
Emerging medicines to improve the basic defect in cystic fibrosis11
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia10
Emerging biological treatments for asthma10
Emerging injectable therapies for osteoarthritis9
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials9
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?9
Cannabinoid treatment for the symptoms of autism spectrum disorder8
Emerging drugs for the treatment of herpetic keratitis8
Expert opinion on emerging drugs for lung chronic graft-versus-host disease7
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria7
A review of emerging factor XI inhibitors7
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?7
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials7
Recent advances in immune-based approaches for the treatment of esophagogastric cancer6
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder6
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion6
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials6
Emerging antiviral therapies and drugs for the treatment of influenza5
Correction5
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma5
How will tovorafenib change our treatment of pediatric low-grade glioma?5
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma5
Emerging tyrosine kinase inhibitors for head and neck cancer5
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials5
0.067464113235474